News & Updates
Filter by Specialty:
Trastuzumab deruxtecan shows promise in metastatic breast cancer
Treatment with trastuzumab deruxtecan (T-DXd) provides sustained antitumour activity and shows a consistent safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1), as shown by the updated survival results from the phase II DESTINY-Breast01 trial.
Trastuzumab deruxtecan shows promise in metastatic breast cancer
03 Mar 2024
Is MFS a valid surrogate for OS in prostate cancer?
Metastasis-free survival (MFS) is still a good proxy for overall survival (OS) as endpoint in the current era, wherein patients have more access to docetaxel and other treatments for metastatic castrate-resistant prostate cancer (mCRPC), according to a study.
Is MFS a valid surrogate for OS in prostate cancer?
02 Mar 2024
Which factors predict mortality in advanced HCC?
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
Which factors predict mortality in advanced HCC?
01 Mar 2024
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
01 Mar 2024
Interactive multistage robotic positioner developed for intraoperative MRI-guided stereotactic neurosurgery
A joint multidisciplinary team of researchers from the Chinese University of Hong Kong (CUHK), the University of Hong Kong (HKU), University College London, and Johns Hopkins University has developed an interactive, multistage robotic positioner for intraoperative MRI-guided stereotactic neurosurgery aimed at treating patients with neurological diseases, such as brain tumours and Parkinson’s disease.
Interactive multistage robotic positioner developed for intraoperative MRI-guided stereotactic neurosurgery
01 Mar 2024
SBRT on par with HART in limited-stage small-cell lung cancer
Stereotactic body radiotherapy (SBRT) is a safe and effective alternative to hyperfractionated accelerated radiotherapy (HART) in the treatment of limited-stage small-cell lung cancer (LS-SCLC), suggests a recent study.
SBRT on par with HART in limited-stage small-cell lung cancer
29 Feb 2024
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.